 Tiziana Life Sciences Ltd NASDAQ:TLSA highlighted milestones from the first six months of 2022 as the company advances its pipeline of next-generation therapeutics and diagnostics for oncology and immune diseases of high unmet demand. In its interim results for the six months to June 30, 2022, the companys RD expenses increased from 5.6 million in the first half of 2021 to 7.5 million which it attributed to the advancement of Tizianas proprietary programs TZLS-401 and TZLS-501. 